Updates are available Correction dated 2025-09-13

Article History

Accepted: 24 July 2025

First Online: 7 August 2025

Change Date: 18 August 2026

Change Type: Update

Change Details: Graphical abstract and the drug names are updated. Video abstract and the slide deck have been included in the original publication.

Change Date: 13 September 2025

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1007/s40263-025-01224-1

Declarations

Funding: The authors received no funding for the development of this work. Medical writing and creative and editorial assistance were provided by Ogilvy Health UK and funded by UCB. The open access fee was paid by UCB.

Conflicts of interest: K.D. has received honorarium from Crossject, Neurelis, and UCB for participating in advisory board meetings. AS has received personal fees and grants from Angelini Pharma, Biocodex, Desitin Arzneimittel, Eisai, Jazz Pharmaceuticals, Neuraxpharm, Takeda, UCB Pharma, and UNEEG Medical. J.C.C. serves as an advisory board member for Neurelis, serves as a consultant for Crossject, and has received research grants from PrevEp and Allaysis. R.R., C.L., and H.C. are employed by UCB.

Ethics approval: Not applicable.

Consent to participate: Not applicable.

Consent for publication: Not applicable.

Availability of data and material: Not applicable.

Code availability: Not applicable.

Author contributions: K.D.: conceptualization, writing—review and editing. A.S.: conceptualization, writing—review and editing. R.R.: conceptualization, writing—review and editing. C.L.: conceptualization, writing—review and editing, funding acquisition. H.C.: conceptualization, writing—review and editing. J.C.C.: conceptualization, writing—review and editing. All authors have read and approved the final submitted manuscript and agree to be accountable for the work.